Literature DB >> 27246533

The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC.

Chunbo Wang1,2, Huan Nie1, Yiqun Li1, Guiyou Liu1,3, Xu Wang4, Shijie Xing1, Liping Zhang2, Xin Chen2, Yue Chen1, Yu Li1.   

Abstract

To analyze the relation between SNPs in DNA repair pathway-related genes and sensitivity of tumor radio-chemotherapy, 26 SNPs in 20 DNA repair genes were genotyped on 176 patients of NSCLC undertaking radio-chemotherapy treatment. In squamous cell carcinoma (SCC), as the rs2228000, rs2228001 (XPC), rs2273953 (TP73), rs2279744 (MDM2), rs2299939 (PTEN) and rs8178085, rs12334811 (DNA-PKcs) affected the sensitivity to chemotherapy, so did the rs8178085, rs12334811 to radiotherapy. Moreover rs344781, rs2273953 and rs12334811 were related with the survival time of SCC. In general, the "good" genotype GG (rs12334811) showed greater efficacy of radio-chemotherapy and MSF (24 months) on SCC. In adenocarcinoma, as the rs2699887 (PIK3), rs12334811 (DNA-PKcs) influenced the sensitivity to chemotherapy, so did the rs2299939, rs2735343 (PTEN) to radiotherapy. And rs402710, rs80270, rs2279744 and rs2909430 impacted the survival time of the adenocarcinoma patients. Both GG (rs2279744) and AG (rs2909430) showed a shorter survival time (MFS = 6). Additionally, some SNPs such as rs2228000, rs2228001 and rs344781 were found to regulate the expression of DNA repair pathway genes through eQTLs dataset analysis. These results indicate that SNPs in DNA repair pathway genes might regulate the expression and affect the DNA damage repair, and thereby impact the efficacy of radio-chemotherapy and the survival time of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27246533      PMCID: PMC4887885          DOI: 10.1038/srep26526

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  59 in total

1.  Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations.

Authors:  Daiki Miki; Michiaki Kubo; Atsushi Takahashi; Kyong-Ah Yoon; Jeongseon Kim; Geon Kook Lee; Jae Ill Zo; Jin Soo Lee; Naoya Hosono; Takashi Morizono; Tatsuhiko Tsunoda; Naoyuki Kamatani; Kazuaki Chayama; Takashi Takahashi; Johji Inazawa; Yusuke Nakamura; Yataro Daigo
Journal:  Nat Genet       Date:  2010-09-26       Impact factor: 38.330

2.  Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.

Authors:  Daniela F Giachino; Paolo Ghio; Silvia Regazzoni; Giorgia Mandrile; Silvia Novello; Giovanni Selvaggi; Dario Gregori; Mario DeMarchi; Giorgio V Scagliotti
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

Review 3.  Detection and repair of ionizing radiation-induced DNA double strand breaks: new developments in nonhomologous end joining.

Authors:  Chen Wang; Susan P Lees-Miller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-20       Impact factor: 7.038

4.  Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.

Authors:  Youngjoo Lee; Kyong-Ah Yoon; Jungnam Joo; Donghoon Lee; Kieun Bae; Ji-Youn Han; Jin Soo Lee
Journal:  Carcinogenesis       Date:  2012-11-08       Impact factor: 4.944

5.  A rigorous and comprehensive validation: common genetic variations and lung cancer.

Authors:  Ping Yang; Yafei Li; Ruoxiang Jiang; Julie M Cunningham; Yan Li; Fang Zhang; Mariza de Andrade
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

6.  Annual report on status of cancer in China, 2010.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Hongmei Zeng; Xiaonong Zou; Jie He
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

7.  Activation of AKT/ERK confers non-small cell lung cancer cells resistance to vinorelbine.

Authors:  Da-Ping Fan; Yi-Mei Zhang; Xiao-Chen Hu; Jing-Jing Li; Wei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

Review 8.  DNA repair and cisplatin resistance in non-small-cell lung cancer.

Authors:  Rafael Rosell; Reginald V N Lord; Miquel Taron; Noemi Reguart
Journal:  Lung Cancer       Date:  2002-12       Impact factor: 5.705

Review 9.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

Authors:  Lindsey D Mayo; David B Donner
Journal:  Trends Biochem Sci       Date:  2002-09       Impact factor: 13.807

Review 10.  The DNA damage response and cancer therapy.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

View more
  10 in total

1.  Potential Functional Variants in DNA Repair Genes Are Associated with Efficacy and Toxicity of Radiotherapy in Patients with Non-Small-Cell Lung Cancer.

Authors:  Zhiguang Yang; Zhaoyu Liu
Journal:  J Oncol       Date:  2020-06-24       Impact factor: 4.375

2.  The Genomic Landscape of Corticotroph Tumors: From Silent Adenomas to ACTH-Secreting Carcinomas.

Authors:  Sergio Andonegui-Elguera; Gloria Silva-Román; Eduardo Peña-Martínez; Keiko Taniguchi-Ponciano; Sandra Vela-Patiño; Ilan Remba-Shapiro; Erick Gómez-Apo; Ana-Laura Espinosa-de-Los-Monteros; Lesly A Portocarrero-Ortiz; Gerardo Guinto; Sergio Moreno-Jimenez; Laura Chavez-Macias; Renata Saucedo; Lourdes Basurto-Acevedo; Blas Lopez-Felix; Carolina Gonzalez-Torres; Javier Gaytan-Cervantes; Jorge T Ayala-Sumuano; Andres Burak-Leipuner; Daniel Marrero-Rodríguez; Moisés Mercado
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

3.  Association of phosphatase and tension homologue deleted on chromosome ten polymorphism rs1903858, but not serum levels with the risk of non-small-cell lung cancer: A case-control study.

Authors:  Zhen Liang; Yuzhu Tang; Hao Li; Youjun Xie; Lingling Zhan
Journal:  J Clin Lab Anal       Date:  2020-06-15       Impact factor: 2.352

4.  Genetic polymorphisms of lncRNA-p53 regulatory network genes are associated with concurrent chemoradiotherapy toxicities and efficacy in nasopharyngeal carcinoma patients.

Authors:  Youhong Wang; Zhen Guo; Yu Zhao; Yi Jin; Liang An; Bin Wu; Zhaoqian Liu; Xiaoping Chen; Xiang Chen; Honghao Zhou; Hui Wang; Wei Zhang
Journal:  Sci Rep       Date:  2017-08-16       Impact factor: 4.379

5.  Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma.

Authors:  Katja Goričar; Viljem Kovač; Vita Dolžan
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

6.  MassArray analysis of genomic susceptibility variants in ovarian cancer.

Authors:  Sonali Verma; Indu Sharma; Varun Sharma; Amrita Bhat; Ruchi Shah; Gh Rasool Bhat; Bhanu Sharma; Divya Bakshi; Ashna Nagpal; Ajay Wakhloo; Audesh Bhat; Rakesh Kumar
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

7.  XPG is Modulated by miR-4715-3p and rs873601 Genotypes in Lung Cancer.

Authors:  WeiLing Yu; JinJian Yao; Pengfei Lyu; Jing Zhou; Xiaoxi Chen; Xiaoran Liu; Sha Xiao
Journal:  Cancer Manag Res       Date:  2021-04-19       Impact factor: 3.989

8.  The Relevance of Regenerating Gene 1a Polymorphisms to Radiation Sensitivity and Survival of Nasopharyngeal Carcinoma Receiving Radiotherapy in a Southern Chinese Population.

Authors:  Hai-Jie Xing; Xiang-Dong Chen; Hong-Xia Sun; Yao-Zhang Dai; Yao-Feng Han; Hai-Bo Chen; Feng Liu
Journal:  Pharmgenomics Pers Med       Date:  2021-11-06

9.  Association between common polymorphisms in ERCC gene and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis.

Authors:  Chunpu Li; Xin Yu; Dongmei Guo; Guanhua Liu; Kaigang Zhang; Qingliang Teng; Hai Lin
Journal:  Onco Targets Ther       Date:  2018-06-18       Impact factor: 4.147

10.  Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients.

Authors:  Francesca Morgese; Davide Soldato; Silvia Pagliaretta; Riccardo Giampieri; Donatella Brancorsini; Mariangela Torniai; Silvia Rinaldi; Agnese Savini; Azzurra Onofri; Marina Scarpelli; Rossana Berardi
Journal:  Oncotarget       Date:  2017-05-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.